Page 70 - Read Online

Page 66 Griffiths et al. Neuroimmunol Neuroinflammation 2020;7:51-67 I http://dx.doi.org/10.20517/2347-8659.2019.21

quantitative 7 T imaging. Brain 2015;138:932-45.
34. Absinta M, Vuolo L, Rao A, Nair G, Sati P, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple
sclerosis. Neurology 2015;85:18-28.
35. Zurawski J, Tauhid S, Chu R, Khalid F, Healy BC, et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting
multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler 2020;26:177-87.
36. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007;68:634-42.
37. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, et al. Inflammatory cortical demyelination in early multiple sclerosis.
N Engl J Med 2011;365:2188-97.
38. Guseo A, Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975;211:51-60.
39. Adams CW. Pathology of multiple sclerosis: progression of the lesion. Br Med Bull 1977;33:15-20.
40. Dawson JW. XVIII.-the histology of disseminated sclerosis. Trans R Soc Edinburgh 1916;50:517-740.
41. Howell OW, Schulz-Trieglaff EK, Carassiti D, Gentleman SM, Nicholas R, et al. Extensive grey matter pathology in the cerebellum in
multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol Appl Neurobiol 2015;41:798-813.
42. DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1
on spinal cord pathology. Brain 2013;136:1025-34.
43. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, et al. Meningeal T cells associate with diffuse axonal loss in multiple
sclerosis spinal cords. Ann Neurol 2010;68:465-76.
44. Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the
pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 2007;502:236-60.
45. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, et al. Meningeal inflammation plays a role in the pathology of primary
progressive multiple sclerosis. Brain 2012;135:2925-37.
46. Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, et al. Cortical grey matter demyelination can be induced by elevated
pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 2013;136:3596-608.
47. Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, et al. Inflammatory intrathecal profiles and cortical damage in multiple
sclerosis. Ann Neurol 2018;83:739-55.
48. Magliozzi R, Hametner S, Facchiano F, Marastoni D, Rossi S, et al. Iron homeostasis, complement, and coagulation cascade as CSF
signature of cortical lesions in early multiple sclerosis. Ann Clin Transl Neurol 2019;6:2150-63.
49. Schirmer L, Velmeshev D, Holmqvist S, Kaufmann M, Werneburg S, et al. Neuronal vulnerability and multilineage diversity in multiple
sclerosis. Nature 2019;573:75-82.
50. Watkins LM, Neal JW, Loveless S, Michailidou I, Ramaglia V, et al. Complement is activated in progressive multiple sclerosis cortical
grey matter lesions. J Neuroinflammation 2016;13:161.
51. Klaver R, Popescu V, Voorn P, Galis-de Graaf Y, van der Valk P, et al. Neuronal and axonal loss in normal-appearing gray matter and
subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol 2015;74:453-8.
52. Jürgens T, Jafari M, Kreutzfeldt M, Bahn E, Brück W, et al. Reconstruction of single cortical projection neurons reveals primary spine
loss in multiple sclerosis. Brain 2016;139:39-46.
53. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple
sclerosis lesions. Ann Neurol 2001;50:389-400.
54. Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, et al. Disease-specific molecular events in cortical multiple sclerosis lesions.
Brain 2013;136:1799-815.
55. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011;134:1914-24.
56. Witte ME, Nijland PG, Drexhage JAR, Gerritsen W, Geerts D, et al. Reduced expression of PGC-1α partly underlies mitochondrial
changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013;125:231-43.
57. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012;8:647-56.
58. Campbell G., Ziabreva I, Reeve A, Krishnan KJ, Reynolds R, et al. Mitochondrial DNA deletions and neurodegeneration in multiple
sclerosis. Ann Neurol 2011;69:481-92.
59. Ofengeim D, Ito Y, Trapp B, Zhang Y, Shan B, et al. Activation of necroptosis in multiple sclerosis. Cell Rep 2015;10:1836-49.
60. Magliozzi R, Howell OW, Durrenberger P, Aricò E, James R, et al. Meningeal inflammation changes the balance of TNF signalling in
cortical grey matter in multiple sclerosis. J Neuroinflammation 2019;16:259.
61. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, et al. Secretory products of multiple sclerosis B cells are cytotoxic to
oligodendroglia in vitro. J Neuroimmunol 2012;246:85-95.
62. Lisak RP, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, et al. B cells from patients with multiple sclerosis induce cell death via
apoptosis in neurons in vitro. J Neuroimmunol 2017;309:88-99.
63. Torkildsen Ø, Stansberg C, Angelskår SM, Kooi EJ, Geurts JJ, et al. Upregulation of immunoglobulin-related genes in cortical sections
from multiple sclerosis patients. Brain Pathol 2010;20:720-9.
64. Crick PJ, Griffiths WJ, Zhang J, Beibel M, Abdel-Khalik J, et al. Reduced plasma levels of 25-hydroxycholesterol and increased
cerebrospinal fluid levels of bile acid precursors in multiple sclerosis patients. Mol Neurobiol 2017;54:8009-20.
65. Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, et al. Cerebrospinal fluid ceramides from patients with multiple sclerosis
impair neuronal bioenergetics. Brain 2014;137:2271-86.
66. Castle D, Wynford-Thomas R, Loveless S, Bentley E, Howell OW, et al. Using biomarkers to predict clinical outcomes in multiple
sclerosis. Pract Neurol 2019;19:342-9.